Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference



Celcuity (NASDAQ:CELC) CEO and co-founder Brian Sullivan outlined the company’s clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference. Sullivan described Celcuity as a clinical-stage oncology



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *